Drugs / SPN-538
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04050293 | Jul 2020 → Mar 2023 | migraine disorder | Supernus Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPN-538 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04050293 ↗ |
| Known as | Topiramate | “SPN-538 (Topiramate XR capsule)” NCT04050293 ↗ |
| Route | Oral | “administered as a single oral dose once a day (QD)” NCT04050293 ↗ |